Abstract:Tripartite-motif protein-56 (TRIM56) positively regulates the induction of type I interferon response via the TLR3 pathway by enhancing IRF3 activation and depends on its C-terminal residues 621-750 for interacting with the adaptor TRIF. However, the precise underlying mechanism and detailed TRIM56 determinants remain unclear. Herein, we show ectopic expression of murine TRIM56 also enhances TLR3-dependent interferon-β promoter activation, suggesting functional conservation. We found that endogenous TRIM56 and TRIF formed a complex early (0.5-2 h) after poly-I:C stimulation and that TRIM56 overexpression also promoted activation of NF-κB by poly-I:C but not that by TNF-α or IL-1β, consistent with a specific effect on TRIF prior to the bifurcation of NF-κB and IRF3. Using transient transfection and Tet-regulated cell lines expressing various TRIM56 mutants, we demonstrated the Coiled-coil domain and a segment spanning residues ∼434-610, but not the B-box or residues 355-433, were required for TRIM56 augmentation of TLR3 signaling. Moreover, alanine substitution at each putative phosphorylation site, Ser471, Ser475, and Ser710, abrogated TRIM56 function. Concordantly, mutants bearing Ser471Ala, Ser475Ala, or Ser710Ala, or lacking the Coiled-coil domain, all lost the capacity to enhance poly-I:C-induced establishment of an antiviral state. Furthermore, the Ser710Ala mutation disrupted the TRIM56-TRIF association. Using phospho-specific antibodies, we detected biphasic phosphorylation of TRIM56 at Ser471 and Ser475 following TLR3 stimulation, with the early phase occurring at ∼0.5 to 1 h, prior to IRF3 phosphorylation. Together, these data reveal novel molecular details critical for the TRIM56 augmentation of TLR3-dependent antiviral response and highlight important roles for TRIM56 scaffolding and phosphorylation.

Key roles for phosphorylation and the Coiled-coil domain in TRIM56-mediated positive regulation of TLR3-TRIF-dependent innate immunity

TRIM38 Negatively Regulates TLR3-mediated IFN-β Signaling by Targeting TRIF for Degradation.

TRIM 30 a negatively regulates TLR-mediated NF-j B activation by targeting TAB 2 and TAB 3 for degradation

Impaired Antiviral Responses to Extracellular Double-Stranded RNA and Cytosolic DNA, but Not to Interferon-α Stimulation, in TRIM56-Deficient Cells.

Trim30 Alpha Negatively Regulates Tlr-Mediated Nf-Kappa B Activation By Targeting Tab2 And Tab3 For Degradation

TRIM30α negatively regulates TLR-mediated NF-κB activation by targeting TAB2 and TAB3 for degradation

Trim38 Negatively Regulates Tlr3/4-Mediated Innate Immune and Inflammatory Responses by Two Sequential and Distinct Mechanisms

TRIM28 facilitates type I interferon activation by targeting TBK1

TRIM65 regulates innate immune signaling by enhancing K6-linked ubiquitination of IRF3 and its chromatin recruitment

TRIM26 negatively regulates interferon-β production and antiviral response through polyubiquitination and degradation of nuclear IRF3.

TRIM8 Negatively Regulates TLR3/4-Mediated Innate Immune Response by Blocking TRIF–TBK1 Interaction

TRIM21 is Essential to Sustain IFN Regulatory Factor 3 Activation During Antiviral Response

TRIM14 is a key regulator of the type I interferon response during Mycobacterium tuberculosis infection

Analysis of a TIR-less Splice Variant of TRIF Reveals an Unexpected Mechanism of TLR3-mediated Signaling

Multifaceted Roles of TRIM38 in Innate Immune and Inflammatory Responses

InTRIMsic immunity: Positive and negative regulation of immune signaling by tripartite motif proteins

E3 ubiquitin ligase tripartite motif 7 positively regulates the TLR4-mediated immune response via its E3 ligase domain in macrophages.

P300, but not PCAF, collaborates with IRF-1 in stimulating TRIM22 expression, that is independent on its histone acetyltransferase activity

TRIM25 and DEAD-Box RNA Helicase DDX3X Cooperate to Regulate RIG-I-Mediated Antiviral Immunity

TRIM41 is required to innate antiviral response by polyubiquitinating BCL10 and recruiting NEMO

Tripartite Motif 8 (TRIM8) Modulates TNFα- and IL-1β–triggered NF-κB Activation by Targeting TAK1 for K63-linked Polyubiquitination